

TriCore Reference Laboratories
 Non-Hospital Antibigram
 Gram Negative Isolates 2010

% Susceptible (A)

ORGANISMS (N)	Ampicillin	Amikacin	Ampicillin/ sulbactam	Aztreonam	Ciprofloxacin	Cefoxitin	Cefepime	Ceftioxone	Ertapenem	Gentamicin	Meropenem	Imipenem	(C) Nitrofurantoin	Piperacillin/ Tazobactam	Trimethoprim/ Sulfamethox.
<i>Acinetobacter baumannii</i> (42)	(-)	100	ND	ND	90.5	ND	83.3	ND	ND	100	95.7	95.5	ND	ND	91.3
<i>Citrobacter freundii</i> (285)	-	100	-	97.8	91.1	-	100	90.0(D)	100	94.4	100	100	94.2	91.9	82.8
<i>Citrobacter koserii</i> (182)	-	100	95.3	100	100	95.3	100	99.5	99.5	99.5	100	100	-	98.9	98.9
<i>Enterobacter aerogenes</i> (330)	-	100	-	88.5	99	-	99.7	85.2(D)	99.4	99.7	100	99.7	-	89.1	99.7
<i>Enterobacter cloacae</i> (417)	-	100	-	92.2	92.1	-	99.8	86.4(D)	97.4	98.6	99.5	99.5	-	87.8	89.7
<i>Escherichia coli</i> (15597)	55	99.9	58.9	95.9	84.5	89	96.1	95.6	100	94	100	100	98.4	96.9	76.9
<i>Klebsiella oxtoca</i> (386)	-	100	-	94.4	95.8	64.8	94.4	93.3	99.5	99	100	100	87.5	90.9	92.2
<i>Klebsiella pneumoniae</i> (2254)	-	100	85.2	97.8	95.7	91.7	98	98.1	99.8	99.7	100	100	-	97.2	93
<i>Morganella morganii</i> (120)	-	100	-	97.6	75.6	-	100	100	99.2	77.5	100	100	-	84.2	62.5
<i>Proteus mirabilis</i> (974)	82.7	99.7	ISD*	98.1	79.9	81.2	99.1	98.7	98.8	93.5	100	ISD*	-	87.8	78.5
<i>Pseudomonas aeruginosa</i> (757)	-	80.1	-	81.2	70.7	-	86.7	ND	-	93.6	ND	91.7	-	97	-
<i>Serratia marcescens</i> (77)	-	100	-	96.1	93.5	-	100	96.1	97.4	98.7	98.7	98.7	-	97.4	ISD*

(-) Antibiotics in white are inactive, not 1st choice drug or resistance is > 50%; shaded bars S ≥ 50%, ND = No data; ISD* = insufficient data.

Data based on 1st isolate per patient and from all culture sites; Data from TriCore EpiCenter and Eurofins®.

A. Data evaluated per CLSI (NCCLS) M100-S20 and M39 documents.

B. Treatment of *Ps. aeruginosa* infections in compromised hosts should include an anti-Pseudomonal beta lactam, to which the isolate is susceptible, in combination with an aminoglycoside, to which the isolate is susceptible.

C. Use for uncomplicated urinary tract infections only.

D. May develop resistance during prolonged therapy.

